Matching articles for "Flublok"
Influenza Vaccine for 2024-2025
The Medical Letter on Drugs and Therapeutics • September 16, 2024; (Issue 1711)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2024-2025 season are
listed in Table 2.
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Influenza Vaccine for 2023-2024
The Medical Letter on Drugs and Therapeutics • October 16, 2023; (Issue 1687)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2023-2024 season
are listed in Table 2.
Influenza Vaccine for 2022-2023
The Medical Letter on Drugs and Therapeutics • October 3, 2022; (Issue 1660)
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023...
Annual vaccination in the US against influenza A and
B viruses is recommended for everyone ≥6 months
old without a contraindication. Influenza vaccines
that are available in the US for the 2022-2023 season
are listed in Table 2.
Influenza Vaccine for 2021-2022
The Medical Letter on Drugs and Therapeutics • October 4, 2021; (Issue 1634)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication.1 Available influenza vaccines for the
2021-2022 season are listed in Table 2.
Influenza Vaccine for 2020-2021
The Medical Letter on Drugs and Therapeutics • September 21, 2020; (Issue 1607)
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness...
Annual vaccination against influenza A and B viruses
is recommended for everyone ≥6 months old without a
contraindication. Vaccination of all eligible persons can
reduce the prevalence of influenza illness and symptoms
that might be confused with those of COVID-19.
Available vaccines and recommendations for specific
patient populations for the 2020-2021 season are listed
in Tables 2 and 3. Lower rates of influenza illness have
been observed this season in the Southern Hemisphere,
probably because of masking, social distancing, school
closures, and travel restrictions.
Influenza Vaccine for 2019-2020
The Medical Letter on Drugs and Therapeutics • October 21, 2019; (Issue 1583)
Annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a contraindication. Available vaccines and
recommendations for specific patient populations for
the...
Annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a contraindication. Available vaccines and
recommendations for specific patient populations for
the 2019-2020 season are listed in Tables 2 and 3.
Influenza Vaccine for 2018-2019
The Medical Letter on Drugs and Therapeutics • October 22, 2018; (Issue 1558)
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and...
Routine annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old. Recommendations for the current season for specific patient populations are listed in Tables 2 and 4.
Influenza Vaccine for 2017-2018
The Medical Letter on Drugs and Therapeutics • October 9, 2017; (Issue 1531)
Routine annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a specific...
Routine annual vaccination against influenza A and B
viruses is recommended for everyone ≥6 months old
without a specific contraindication.
Influenza Vaccine for 2016-2017
The Medical Letter on Drugs and Therapeutics • October 10, 2016; (Issue 1505)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Influenza Vaccine for 2015-2016
The Medical Letter on Drugs and Therapeutics • September 14, 2015; (Issue 1477)
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific...
Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a specific contraindication.
Influenza Vaccine for 2014-2015
The Medical Letter on Drugs and Therapeutics • October 13, 2014; (Issue 1453)
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and...
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and its
complications.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • June 1, 2014; (Issue 142)
Vaccines recommended for adults residing in the
US are reviewed here. Vaccines for travel have been
reviewed separately.
Eight vaccines are currently recommended by the US Advisory Committee on...
Vaccines recommended for adults residing in the
US are reviewed here. Vaccines for travel have been
reviewed separately.
Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Influenza Vaccine for 2013-2014
The Medical Letter on Drugs and Therapeutics • September 16, 2013; (Issue 1425)
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and its
complications. Several new vaccines are available for
the current...
Annual vaccination against influenza A and B viruses
has been shown to decrease influenza illness and its
complications. Several new vaccines are available for
the current season.
In Brief: Two New Seasonal Influenza Vaccines
The Medical Letter on Drugs and Therapeutics • February 4, 2013; (Issue 1409)
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old...
Two new trivalent influenza vaccines, Flucelvax (Novartis) and Flublok (Protein Sciences), will soon be available for prevention of seasonal influenza in adults ≥18 years old (Flucelvax) and 18-49 years old (Flublok). Unlike other available influenza vaccines, neither vaccine is produced in eggs, removing any concern regarding use in egg-allergic patients. Avoiding the use of eggs should allow for faster production of these 2 new vaccines, which could be especially beneficial during a pandemic.
Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is grown in canine kidney cell culture instead of chicken eggs. In an unpublished study summarized in the package insert comparing Flucelvax with placebo in more than 11,000 patients during the 2007-2008 season, the new vaccine was effective in preventing about 84% of cases of influenza due to matching strains and was about 70% effective when non-matching strains were included.
Flublok is produced without use of influenza virus or chicken eggs; a gene that encodes for hemagglutinin antigen (HA) is introduced into baculovirus, a virus that infects insect cells, and the replicating baculovirus produces large amounts of HA. In a study in about 4,600 adults conducted during one influenza season, Flublok was about 45% effective compared to placebo in preventing culture-confirmed influenza despite a significant antigenic mismatch between the vaccine and circulating viruses (96% of circulating strains did not match the vaccine). It was 75% effective in preventing illness caused by matching strains.1
Both Flublok and Flucelvax provide protection against the same strains as the other vaccines available for the 2012-2013 influenza season.2
1. JJ Treanor et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733.
2. Influenza vaccine 2012-2013. Med Lett Drugs Ther 2012; 54:77.
Download complete U.S. English article
Flucelvax is prepared in a similar manner to other influenza vaccines, but the influenza virus is grown in canine kidney cell culture instead of chicken eggs. In an unpublished study summarized in the package insert comparing Flucelvax with placebo in more than 11,000 patients during the 2007-2008 season, the new vaccine was effective in preventing about 84% of cases of influenza due to matching strains and was about 70% effective when non-matching strains were included.
Flublok is produced without use of influenza virus or chicken eggs; a gene that encodes for hemagglutinin antigen (HA) is introduced into baculovirus, a virus that infects insect cells, and the replicating baculovirus produces large amounts of HA. In a study in about 4,600 adults conducted during one influenza season, Flublok was about 45% effective compared to placebo in preventing culture-confirmed influenza despite a significant antigenic mismatch between the vaccine and circulating viruses (96% of circulating strains did not match the vaccine). It was 75% effective in preventing illness caused by matching strains.1
Both Flublok and Flucelvax provide protection against the same strains as the other vaccines available for the 2012-2013 influenza season.2
1. JJ Treanor et al. Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011; 29:7733.
2. Influenza vaccine 2012-2013. Med Lett Drugs Ther 2012; 54:77.
Download complete U.S. English article